Figure 16. 7-Fr balloon-tipped catheter (7 F, single lumen; Arrow Int, Reading, PA), reported by Diab et al. (93). (with permission fromwww.teleflex.com)
Bibliography
1. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983 Nov;141(5):1027–33.
2. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 1998 Jan;53(1):230–42.
3. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–13.
4. Berg KJ. Nephrotoxicity related to contrast media. Scand J Urol Nephrol. 2000 Oct;34(5):317–22.
5. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol. 2001 Jan;12(1):3–9.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002 May 14;105(19):2259–64.
7. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989 Jan 19;320(3):143–9.
8. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med. 1989 Jan 19;320(3):149–53.
9. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med. 1990 Jun;150(6):1237–42.
10. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999 Feb;33(2):403–11.
11. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983 Feb;74(2):243–8.
12. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003 Dec;181(6):1463–71.
13. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002 Oct 16;40(8):1383–8.
14. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl. 2006 Apr;(100):S16-9.
15. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002 Jul 17;40(2):298–303.
16. Baker CSR, Wragg A, Kumar S, De Palma R, Baker LRI, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003 Jun 18;41(12):2114–8.
17. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997 Nov;103(5):368–75.
18. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000 Nov 1;36(5):1542–8.
19. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004 Nov 2;44(9):1763–71.
20. Thomsen HS. Current evidence on prevention and management of contrast-induced nephropathy. Eur Radiol. 2007 Dec;17 Suppl 6:F33-7.
21. Solomon R, Deray G, Consensus Panel for CIN. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006 Apr;(100):S51-3.
22. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98(6A):59K-77K.
23. McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016 Sep 27;68(13):1465–73.
24. Nanayakkara S, Kaye DM. Device Based Approaches to the Prevention of Contrast-Induced Acute Kidney Injury. Interv Cardiol Clin. 2020 Jul;9(3):395–401.
25. Brar SS, Shen AY-J, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008 Sep 3;300(9):1038–46.
26. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008 Aug 19;52(8):599–604.
27. Mautone A, Brown JR. Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J Interv Cardiol. 2010 Feb;23(1):78–85.
28. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv. 2008 Jan 1;71(1):62–72.
29. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008 Jan;3(1):281–7.
30. Venkataraman R. Can we prevent acute kidney injury? Crit Care Med. 2008 Apr;36(4 Suppl):S166-71.
31. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006 Jan;151(1):140–5.
32. Davidson C, Stacul F, McCullough PA, Tumlin J, Adam A, Lameire N, et al. Contrast medium use. Am J Cardiol. 2006 Sep 18;98(6A):42K-58K.
33. Aspelin P, Aubry P, Fransson S-G, Strasser R, Willenbrock R, Berg KJ, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003 Feb 6;348(6):491–9.
34. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 2005 Nov;68(5):2256–63.
35. Jo S-H, Youn T-J, Koo B-K, Park J-S, Kang H-J, Cho Y-S, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006 Sep 5;48(5):924–30.
36. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006 Aug 15;48(4):692–9.
37. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006 Nov;41(11):815–21.
38. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007 Jun 26;115(25):3189–96.
39. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2009 Jul;2(7):645–54.
40. From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. Circ Cardiovasc Interv. 2010 Aug;3(4):351–8.
41. Vogt B, Ferrari P, Schönholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001 Dec 15;111(9):692–8.
42. Cruz DN, Perazella MA, Bellomo R, Corradi V, de Cal M, Kuang D, et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis. 2006 Sep;48(3):361–71.
43. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003 Oct 2;349(14):1333–40.
44. Flaherty MP, Pant S, Patel SV, Kilgore T, Dassanayaka S, Loughran JH, et al. Hemodynamic Support With a Microaxial Percutaneous Left Ventricular Assist Device (Impella) Protects Against Acute Kidney Injury in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circ Res. 2017 Feb 17;120(4):692–700.
45. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011 Sep 13;124(11):1260–9.
46. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012 Jan;5(1):90–7.
47. Stone GW, Vora K, Schindler J, Diaz C, Mann T, Dangas G, et al. Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN Randomized Trial). Am J Cardiol. 2011 Sep 1;108(5):741–6.
48. Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation. 2012 Jul 17;126(3):296–303.
49. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328–34.
50. Briguori C, Airoldi F, D’Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007 Mar 13;115(10):1211–7.
51. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004 Nov 2;110(18):2837–42.
52. Neumayer HH, Junge W, Küfner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant. 1989;4(12):1030–6.
53. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003 Nov 5;290(17):2284–91.
54. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2004 Aug 18;44(4):762–5.
55. Caixeta A, Dogan O, Weisz G. Contrast-induced nephropathy: protective role of fenoldopam. Clin Exp Pharmacol Physiol. 2012 Jun;39(6):497–505.
56. Kapoor A, Sinha N, Sharma RK, Shrivastava S, Radhakrishnan S, Goel PK, et al. Use of dopamine in prevention of contrast induced acute renal failure–a randomised study. Int J Cardiol. 1996 Mar;53(3):233–6.
57. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998 Apr;31(4):674–80.
58. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009 Mar 24;53(12):1040–6.
59. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med. 2005 May 23;165(10):1087–93.
60. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004 Oct;62(4):273–8.
61. Jo S-H, Koo B-K, Park J-S, Kang H-J, Cho Y-S, Kim Y-J, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial–a randomized controlled study. Am Heart J. 2008 Mar;155(3):499.e1-8.
62. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010 Feb 1;105(3):288–92.
63. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003 Jul;59(3):338–43.
64. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct 6;44(7):1393–9.
65. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009 Feb 3;150(3):170–7.
66. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989 Jun;86(6 Pt 1):649–52.
67. Lee S-R, Zhuo H, Zhang Y, Dahl N, Dardik A, Ochoa Chaar CI. Risk factors and safe contrast volume thresholds for postcontrast acute kidney injury after peripheral vascular interventions. J Vasc Surg. 2020 Aug;72(2):603-610.e1.
68. Kooiman J, Seth M, Share D, Dixon S, Gurm HS. The association between contrast dose and renal complications post PCI across the continuum of procedural estimated risk. PLoS ONE. 2014 Mar 13;9(3):e90233.
69. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol. 2008 Jan 1;51(1):89–90.
70. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990 Nov;89(5):615–20.
71. Rozenbaum Z, Benchetrit S, Rozenbaum E, Neumark E, Mosseri M, Pereg D. Ultra-Low Contrast Volume for Patients with Advanced Chronic Kidney Disease Undergoing Coronary Procedures. Nephron. 2018 Jan 24;138(4):296–302.
72. Kelly SC, Li S, Stys TP, Thompson PA, Stys AT. Reduction in Contrast Nephropathy From Coronary Angiography and Percutaneous Coronary Intervention With Ultra-Low Contrast Delivery Using an Automated Contrast Injector System. J Invasive Cardiol. 2016 Nov;28(11):446–50.
73. Azzalini L, Laricchia A, Regazzoli D, Mitomo S, Hachinohe D, Bellini B, et al. Ultra-Low Contrast Percutaneous Coronary Intervention to Minimize the Risk for Contrast-Induced Acute Kidney Injury in Patients With Severe Chronic Kidney Disease. J Invasive Cardiol. 2019 Jun;31(6):176–82.
74. Mariani J, Guedes C, Soares P, Zalc S, Campos CM, Lopes AC, et al. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial. JACC Cardiovasc Interv. 2014 Nov;7(11):1287–93.
75. Do C. Intravenous Contrast: Friend or Foe? A Review on Contrast-Induced Nephropathy. Adv Chronic Kidney Dis. 2017 May;24(3):147–9.
76. Mehran R, Faggioni M, Chandrasekhar J, Angiolillo DJ, Bertolet B, Jobe RL, et al. Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography. JACC Cardiovasc Interv. 2018 Aug 27;11(16):1601–10.
77. Gurm HS, Mavromatis K, Bertolet B, Kereiakes DJ, Amin AP, Shah AP, et al. Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVertTM plus contrast reduction system. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1228–35.
78. Gurm HS, Smith D, Share D, Wohns D, Collins J, Madala M, et al. Impact of automated contrast injector systems on contrast use and contrast-associated complications in patients undergoing percutaneous coronary interventions. JACC Cardiovasc Interv. 2013 Apr;6(4):399–405.
79. Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol. 2014 Jan 1;113(1):49–53.
80. Stub D, Duffy SJ, Kaye DM. Device-Based Therapy in the Prevention of Contrast-Induced Nephropathy. Interv Cardiol Clin. 2014 Jul;3(3):421–8.
81. Sirajuddin A, Chen MY, White CS, Arai AE. Coronary venous anatomy and anomalies. J Cardiovasc Comput Tomogr. 2020;14(1):80–6.
82. Shah SS, Teague SD, Lu JC, Dorfman AL, Kazerooni EA, Agarwal PP. Imaging of the coronary sinus: normal anatomy and congenital abnormalities. Radiographics. 2012 Aug;32(4):991–1008.
83. Boonyasirinant T, Halliburton SS, Schoenhagen P, Lieber ML, Flamm SD. Absence of coronary sinus tributaries in ischemic cardiomyopathy: An insight from multidetector computed tomography cardiac venographic study. J Cardiovasc Comput Tomogr. 2016 Apr;10(2):156–61.
84. Younger JF, Plein S, Crean A, Ball SG, Greenwood JP. Visualization of coronary venous anatomy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009 Aug 11;11:26.
85. Saremi F, Muresian H, Sánchez-Quintana D. Coronary veins: comprehensive CT-anatomic classification and review of variants and clinical implications. Radiographics. 2012 Feb;32(1):E1-32.
86. Movahed M-R, Wong J, Molloi S. Removal of iodine contrast from coronary sinus in swine during coronary angiography. J Am Coll Cardiol. 2006 Jan 17;47(2):465–7.
87. Michishita I, Fujii Z. A novel contrast removal system from the coronary sinus using an adsorbing column during coronary angiography in a porcine model. J Am Coll Cardiol. 2006 May 2;47(9):1866–70.
88. Chang H, Hassan AHM, Kim YL, Lloyd LJ, Koo B-K, Ako J, et al. A Novel Technique for Endovascular Detection and Removal of Radiographic Contrast during Angiography. J Invasive Cardiol. 2009 Jul;21(7):314–8.
89. Meyer M, Dauerman HL, Bell SP, Lewinter MM, Lustgarten DL. Coronary venous capture of contrast during angiography. J Interv Cardiol. 2006 Oct;19(5):401–4.
90. Danenberg HD, Lotan C, Varshitski B, Rosenheck S, Weiss AT. Removal of contrast medium from the coronary sinus during coronary angiography: feasibility of a simple and available technique for the prevention of nephropathy. Cardiovasc Revasc Med. 2008 Mar;9(1):9–13.
91. Duffy SJ, Ruygrok P, Juergens CP, Sievert H, Richards M, Blake J, et al. Removal of contrast media from the coronary sinus attenuates renal injury after coronary angiography and intervention. J Am Coll Cardiol. 2010 Aug 3;56(6):525–6.
92. Juergens CP, Winter JP, Nguyen-Do P, Lo S, French JK, Hallani H, et al. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. Intern Med J. 2009 Jan;39(1):25–31.
93. Diab OA, Helmy M, Gomaa Y, El-Shalakany R. Efficacy and Safety of Coronary Sinus Aspiration During Coronary Angiography to Attenuate the Risk of Contrast-Induced Acute Kidney Injury in Predisposed Patients. Circ Cardiovasc Interv. 2017 Jan;10(1):e004348.
94. Watson T, Burd JS, Ruygrok PN. Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral vein. Int J Cardiol. 2013 Apr 30;165(1):e9-10.
95. Matsuhashi H, Hasebe N, Kawamura Y. The effect of intermittent coronary sinus occlusion on coronary sinus pressure dynamics and coronary arterial flow. Jpn Circ J. 1992 Mar;56(3):272–85.
96. Pantely GA, Bristow JD, Ladley HD, Anselone CG. Effect of coronary sinus occlusion on coronary flow, resistance, and zero flow pressure during maximum vasodilatation in swine. Cardiovasc Res. 1988 Feb;22(2):79–86.
97. Langenberg CJM, Pietersen HG, Geskes G, Wagenmakers AJM, Soeters PB, Durieux M. Coronary sinus catheter placement: assessment of placement criteria and cardiac complications. Chest. 2003 Oct;124(4):1259–65.
98. Sethna DH, Moffitt EA. An appreciation of the coronary circulation. Anesth Analg. 1986 Mar;65(3):294–305.
99. Specchia G, De Servi S, Poma E, Ghio S, Ferrario M, Angoli L, et al. Clinical application of monitoring techniques: coronary sinus blood flow monitoring. Can J Cardiol. 1986 Jul;Suppl A:170A-172A.
100. Zheng Z, Wu B, Chen Q, Luo Y, Tang X, Wang J, et al. The feasibility and safety of a simple method for coronary sinus blood sampling during catheter ablation of arrhythmias. Ann Transl Med. 2022 Feb;10(4):170.